One area of the market where stocks can be found to produce 10x, even 20x returns, regardless of what’s happening elsewhere in the market, is biotech. Looking at the performance of the past ten years, if the biotechnology industry were a sector, it would be the best-performing one. Over the past decade, biotech stocks have returned 524%. That beats every last sector, it beats the broader healthcare sector by 200 percentage points, and it’s nearly double the S&P 500’s total return in that same time frame.
Specifically, genomics is one niche within the biotech group that could offer unimaginable returns. Still, the technology is so new and so complex many investors shy away from companies that are making astounding advancements.
There’s clearly money to be made in the discovery of new treatments for anything from the flu to cancer. But genomics stocks carry substantial risk. While positive data from a trial could send their stocks soaring, a setback or failure can crush their returns, making them difficult buy-and-hold investments.
Today we’re highlighting a rare, buy-and-hold genomics investment that provides ground-floor access to the innovators of tomorrow, along with their potential nose-bleed returns, while minimizing risk.
A company with 400 million ‘patents’
One company has quietly compiled more than 400 million official trade secrets.
Trade secrets are like patents in that they protect valuable and proprietary information…
But unlike patents, trade secrets take less time to register… and more importantly, they never expire.
Which is a huge advantage for this little-known company.
You see, this company is using these trade secrets to build the world’s largest “codebase,” which will bethe key to it becoming “America’s Next Big Monopoly.”
Not surprisingly, Wall Street is starting to take notice. And the smart money is already pouring in.
Tech investor Cathie Wood has invested over $80 million already, and Microsoft founder Bill Gates has invested as well.
Get the details here before this story hits the mainstream media.
One solution for anyone who want to benefit from genomics advancements but is lacking in the expertise needed to evaluate individual companies from the group confidently is to delegate individual stock picking to the professionals. In today’s trade, we’ll focus on an exchange-traded fund (ETF) that provides an opportunity for investors who are looking to gain access to companies at the forefront of genomics innovation.
iShares Genomics Immunology and Healthcare ETF (IDNA) holds a concentrated portfolio of global companies in the biopharmaceutical and healthcare equipment and services industries that could benefit from long-term growth and innovation in genomics, immunology, and bioengineering. The fund is passively managed, and holdings are weighted by market cap and are constrained such that no individual security exceeds 4% of the portfolio. The index rebalances semi-annually.